The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: An umbrella review of the evidence from randomised controlled trials

[1]  Dan J Stein,et al.  Implications of the COVID-19 pandemic for people with bipolar disorders: A scoping review , 2021, Journal of Affective Disorders.

[2]  A. Carvalho,et al.  Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review , 2021, World psychiatry : official journal of the World Psychiatric Association.

[3]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[4]  S. Jensen,et al.  Cardiovascular disease in patients with severe mental illness , 2020, Nature Reviews Cardiology.

[5]  R. McIntyre,et al.  The Effect of Loneliness on Distinct Health Outcomes: A Comprehensive Review and Meta-Analysis , 2020, Psychiatry Research.

[6]  C. Correll,et al.  Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics , 2020, Drugs.

[7]  A. Carvalho,et al.  A meta‐review of “lifestyle psychiatry”: the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders , 2020, World psychiatry : official journal of the World Psychiatric Association.

[8]  C. Correll,et al.  Safety of 80 antidepressants, antipsychotics, anti‐attention‐deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta‐review of 78 adverse effects , 2020, World psychiatry : official journal of the World Psychiatric Association.

[9]  Jun Lyu,et al.  Trends in the incidence and DALYs of bipolar disorder at global, regional, and national levels: Results from the global burden of Disease Study 2017. , 2020, Journal of psychiatric research.

[10]  D. Vancampfort,et al.  The Impact of Pharmacologic and Nonpharmacologic Interventions to Improve Physical Health Outcomes in People With Dementia: A Meta-Review of Meta-Analyses of Randomized Controlled Trials. , 2020, Journal of the American Medical Directors Association.

[11]  A. Tanskanen,et al.  20‐year follow‐up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20) , 2020, World psychiatry : official journal of the World Psychiatric Association.

[12]  Andrea Cipriani,et al.  Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis , 2020, The lancet. Psychiatry.

[13]  Alejandro Castillo M.,et al.  Consumo de alcohol y diagnóstico de trastorno afectivo bipolar en población adulta colombiana , 2020, Revista Colombiana de Psiquiatría.

[14]  A. Young,et al.  Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review. , 2019, JAMA psychiatry.

[15]  A. Carvalho,et al.  The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. , 2019, The lancet. Psychiatry.

[16]  A. Carvalho,et al.  The impact of pharmacological and non‐pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta‐review of meta‐analyses of randomized controlled trials , 2019, World psychiatry : official journal of the World Psychiatric Association.

[17]  H. Möller,et al.  EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH) , 2018, European Psychiatry.

[18]  J. Calabrese,et al.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder , 2018, Bipolar disorders.

[19]  Joseph Firth,et al.  Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta‐analysis , 2017, World psychiatry : official journal of the World Psychiatric Association.

[20]  P. Sienaert,et al.  Higher cardio-respiratory fitness is associated with increased mental and physical quality of life in people with bipolar disorder: A controlled pilot study , 2017, Psychiatry Research.

[21]  Xiaohong Li,et al.  Prevalence of smoking in patients with bipolar disorder, major depressive disorder and schizophrenia and their relationships with quality of life , 2017, Scientific Reports.

[22]  C. Correll,et al.  Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence , 2017, JAMA psychiatry.

[23]  A. Carvalho,et al.  Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review , 2017, Therapeutics and clinical risk management.

[24]  Paolo Santonastaso,et al.  Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large‐scale meta‐analysis of 3,211,768 patients and 113,383,368 controls , 2017, World psychiatry : official journal of the World Psychiatric Association.

[25]  A. Amare,et al.  The genetic overlap between mood disorders and cardiometabolic diseases: a systematic review of genome wide and candidate gene studies , 2017, Translational Psychiatry.

[26]  D. Vancampfort,et al.  Are lower levels of cardiorespiratory fitness associated with incident depression? A systematic review of prospective cohort studies. , 2016, Preventive medicine.

[27]  R. Lam,et al.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder , 2016, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[28]  Daniel J. Müller,et al.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder , 2016, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[29]  Daniel J. Müller,et al.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder , 2016, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[30]  D. Vancampfort,et al.  Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta‐analysis , 2016, World psychiatry : official journal of the World Psychiatric Association.

[31]  M. Payne,et al.  Nutrition and Bipolar Depression. , 2016, The Psychiatric clinics of North America.

[32]  Klaus P. Ebmeier,et al.  European Psychiatric Association Guidance on psychotherapy in chronic depression across Europe , 2016, European Psychiatry.

[33]  B. Baune,et al.  Anti‐inflammatory agents in the treatment of bipolar depression: a systematic review and meta‐analysis , 2016, Bipolar disorders.

[34]  P. Hyland,et al.  Social, familial and psychological risk factors for mood and anxiety disorders in childhood and early adulthood: a birth cohort study using the Danish Registry System , 2016, Social Psychiatry and Psychiatric Epidemiology.

[35]  D. Vancampfort,et al.  Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis , 2015, World psychiatry : official journal of the World Psychiatric Association.

[36]  P. Andersen,et al.  Causes of decreased life expectancy over the life span in bipolar disorder. , 2015, Journal of affective disorders.

[37]  C. Correll,et al.  Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder , 2015, World psychiatry : official journal of the World Psychiatric Association.

[38]  J. Calabrese,et al.  Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE). , 2015, Bipolar disorders.

[39]  J. Bodegård,et al.  Population study of disease burden, management, and treatment of bipolar disorder in Sweden: a retrospective observational registry study , 2015, Bipolar disorders.

[40]  M. Gissler,et al.  Life Expectancy and Death by Diseases of the Circulatory System in Patients with Bipolar Disorder or Schizophrenia in the Nordic Countries , 2013, PloS one.

[41]  H. Fenn.  Treatment of bipolarity + medical comorbidity = costability , 2012, Acta psychiatrica Scandinavica.

[42]  H. Möller,et al.  Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression , 2012, European Psychiatry.

[43]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[44]  H. Lôo.  [On bipolar disorder]. , 2008, L'Encephale.

[45]  David Moher,et al.  Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews , 2007, BMC medical research methodology.

[46]  J. Kampert,et al.  Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men. , 1999, JAMA.

[47]  Sonia Bersh,et al.  Alcohol Consumption and Bipolar Disorder in a Colombian Population Sample. , 2020 .

[48]  H. Völzke,et al.  Associations of Leisure-Time and Occupational Physical Activity and Cardiorespiratory Fitness With Incident and Recurrent Major Depressive Disorder, Depressive Symptoms, and Incident Anxiety in a General Population. , 2017, The Journal of clinical psychiatry.

[49]  Gary Rodin,et al.  The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. , 2012, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.